Uncategorized
“Real-life” study provides data for anti-VEGF treatment in diverse RVO population
LONDON — The LUMINOUS study, the largest prospective, observational study in medical retina, continues to provide a valuable source of real-world Lucentis data, according to a speaker here.“There is a wealth of ranibizumab (Lucentis, Genentech) evidence available from randomized clinical trials, but real-life studies deal with a more diverse population, providing long-term follow-up data and safety monitoring from a large and varied population that facilitates detection of rare safety events,” Ben J. Burton, MRCP, FRCOphth, said at the Euretina Congress.